| 2026 | Diabetes Fact Sheet 2025: Comparative Epidemiology and Clinical Features of Obese and Non-Obese Diabetes in Korea
| DIABETES & METABOLISM JOURNAL |
| 2026 | Diabetes Fact Sheet 2025: Special Edition on Diabetes with Obesity and in Pregnancy
| DIABETES & METABOLISM JOURNAL |
| 2026 | Efficacy and safety of adding a fourth oral antidiabetic drug versus metformin dose escalation in patients with type 2 diabetes inadequately controlled on triple oral combination therapy (EFFORT): A 24-week, randomized, open-label, multicenter trial | DIABETES OBESITY & METABOLISM |
| 2026 | Lobeglitazone improves glycaemic control as add-on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double-blind, randomised, placebo-controlled trial
| DIABETES OBESITY & METABOLISM |
| 2025 | Efficacy and safety of pioglitazone versus dapagliflozin as an add-on to metformin and alogliptin combination therapy: the EPIDOTE study
| SCIENTIFIC REPORTS |
| 2025 | Protective Role of Serum β-Hydroxybutyrate in Early Diabetic Kidney Disease: A Longitudinal Study
| DIABETES THERAPY |
| 2025 | Comprehensive approaches to diabetes in the elderly: adapting to evolving trends
| KOREAN JOURNAL OF INTERNAL MEDICINE |
| 2025 | Defining Severe Diabetes Mellitus: A Consensus Framework for Grading and Staging Diabetes Based on Pathophysiology and Complications
| DIABETES & METABOLISM JOURNAL |
| 2025 | Bridging Evidence and Practice: A Consensus Statement from the Korean Diabetes Association on Diabetes Screening, Pharmacological Treatment and Severe Diabetes
| DIABETES & METABOLISM JOURNAL |
| 2025 | Trends in Prevalence of Obesity and Related Cardiometabolic and Renal Complications in Korea: A Nationwide Study 2007 to 2022
| JOURNAL OF OBESITY & METABOLIC SYNDROME |
| 2025 | 2025 Clinical Practice Guidelines for Diabetes Management in Korea: Recommendation of the Korean Diabetes Association
| DIABETES & METABOLISM JOURNAL |
| 2025 | Prevalence of mortality and vascular complication in older patients with diabetes in Korea
| Endocrinology and Metabolism(대한내분비학회지) |
| 2025 | Impact of physical activities in metabolic dysfunction associated steatotic liver disease, sarcopenia, and cardiovascular disease | DIABETES RESEARCH AND CLINICAL PRACTICE |
| 2025 | Synergistic benefit of thiazolidinedione and sodium-glucose cotransporter 2 inhibitor for metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: a 24-week, open-label, randomized controlled trial
| BMC MEDICINE |
| 2025 | Effectiveness and Safety of Oral Quadruple Combination Therapy in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis
| Endocrinology and Metabolism(대한내분비학회지) |
| 2025 | Study Design and Protocol for a Randomized Controlled Trial of Enavogliflozin to Evaluate Cardiorenal Outcomes in Type 2 Diabetes (ENVELOP)
| DIABETES & METABOLISM JOURNAL |
| 2025 | Potential Impact of Choline Alphoscerate on Depressive Symptoms in Association with Insulin Resistance in Elderly Patients with Type 2 Diabetes
| JOURNAL OF CLINICAL MEDICINE |
| 2025 | Diabetes Fact Sheets in Korea 2024
| DIABETES & METABOLISM JOURNAL |
| 2024 | Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetes Mellitus: A Review and Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association
| DIABETES & METABOLISM JOURNAL |
| 2024 | Study Design and Protocol for a Randomized Controlled Trial to Assess Long-Term Efficacy and Safety of a Triple Combination of Ezetimibe, Fenofibrate, and Moderate-Intensity Statin in Patients with Type 2 Diabetes and Modifiable Cardiovascular Risk Factors (ENSEMBLE)
| Endocrinology and Metabolism(대한내분비학회지) |
| 2024 | SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes | NEUROLOGY |
| 2024 | Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial | DIABETES & METABOLISM JOURNAL |
| 2024 | 2023 Clinical Practice Guidelines for Diabetes Management in Korea: Full Version Recommendation of the Korean Diabetes Association
| DIABETES & METABOLISM JOURNAL |
| 2024 | Appendicular Skeletal Muscle Mass to Visceral Fat Area Ratio Predicts Hepatic Morbidities
| GUT AND LIVER |
| 2024 | Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study | METABOLISM-CLINICAL AND EXPERIMENTAL |
| 2024 | Intact ketogenesis predicted reduced risk of moderate-severe metabolic-associated fatty liver disease assessed by liver transient elastography in newly diagnosed type 2 diabetes
| FRONTIERS IN ENDOCRINOLOGY |
| 2023 | MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY |
| 2023 | Increased expression of sodium-glucose cotransporter 2 and O-GlcNAcylation in hepatocytes drives non-alcoholic steatohepatitis | METABOLISM-CLINICAL AND EXPERIMENTAL |
| 2023 | The effects of long-term cumulative HbA1c exposure on the development and onset time of dementia in the patients with type 2 diabetes mellitus: Hospital based retrospective study (2005-2021) | DIABETES RESEARCH AND CLINICAL PRACTICE |
| 2023 | β-hydroxybutyrate as a biomarker of β-cell function in new-onset type 2 diabetes and its association with treatment response at 8 months | DIABETES & METABOLISM |
| 2023 | Age at Mortality in Patients with Type 2 Diabetes Who Underwent Kidney Transplantation: An Analysis of Data from the Korean National Health Insurance and Statistical Information Service, 2006 to 2018
| JOURNAL OF CLINICAL MEDICINE |
| 2023 | Impaired ketogenesis is associated with metabolic-associated fatty liver disease in subjects with type 2 diabetes
| FRONTIERS IN ENDOCRINOLOGY |
| 2022 | Fibrotic Burden Determines Cardiovascular Risk among Subjects with Metabolic Dysfunction-Associated Fatty Liver Disease
| GUT AND LIVER |
| 2022 | The effects of the voglibose on non-alcoholic fatty liver disease in mice model
| SCIENTIFIC REPORTS |
| 2022 | Protective Effect of Delta-Like 1 Homolog Against Muscular Atrophy in a Mouse Model
| Endocrinology and Metabolism(대한내분비학회지) |
| 2022 | Effects of a Phosphodiesterase inhibitor on the Browning of Adipose Tissue in Mice
| BIOMEDICINES |
| 2022 | Tolerability and Effectiveness of Switching to Dulaglutide in Patients With Type 2 Diabetes Inadequately Controlled With Insulin Therapy
| FRONTIERS IN ENDOCRINOLOGY |
| 2022 | Improvement in Age at Mortality and Changes in Causes of Death in the Population with Diabetes: An Analysis of Data from the Korean National Health Insurance and Statistical Information Service, 2006 to 2018
| Endocrinology and Metabolism(대한내분비학회지) |
| 2022 | Obesity is an important determinant of severity in newly defined metabolic dysfunction-associated fatty liver disease | HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL |
| 2022 | Sodium Glucose Cotransporter-2 Inhibitors as an Add-on Therapy to Metformin Plus Dipeptidyl Peptidase-4 Inhibitor in Patients with Type 2 Diabetes
| YONSEI MEDICAL JOURNAL |
| 2022 | Short Term Isocaloric Ketogenic Diet Modulates NLRP3 Inflammasome Via B-hydroxybutyrate and Fibroblast Growth Factor 21
| FRONTIERS IN IMMUNOLOGY |
| 2022 | Severe Hypoglycemia Increases Dementia Risk and Related Mortality: A Nationwide, Population-based Cohort Study | JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM |
| 2022 | Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study)
| BMC MEDICINE |
| 2022 | Cardiovascular Risk Is Elevated in Lean Subjects with Nonalcoholic Fatty Liver Disease
| GUT AND LIVER |
| 2022 | Analysis of Severe Hypoglycemia Among Adults With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
| JAMA NETWORK OPEN |
| 2022 | Renal Tubular Damage Marker, Urinary N-acetyl-β-D-Glucosaminidase, as a Predictive Marker of Hepatic Fibrosis in Type 2 Diabetes Mellitus
| DIABETES & METABOLISM JOURNAL |
| 2022 | Blood Pressure Levels and Risks of Dementia: a Nationwide Study of 4.5 Million People | HYPERTENSION |
| 2021 | Uric Acid Variability as a Predictive Marker of Newly Developed Cardiovascular Events in Type 2 Diabetes
| FRONTIERS IN CARDIOVASCULAR MEDICINE |
| 2021 | Proteinuria as a significant predictive factor for the progression of carotid artery atherosclerosis in non-albuminuric type 2 diabetes | DIABETES RESEARCH AND CLINICAL PRACTICE |
| 2021 | Ipragliflozin, an SGLT2 Inhibitor, Ameliorates High-Fat Diet-Induced Metabolic Changes by Upregulating Energy Expenditure through Activation of the AMPK/ SIRT1 Pathway
| DIABETES & METABOLISM JOURNAL |
http://orcid.org/0000-0003-0542-2854
(7007118478)
